Biotech News

Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026

Zentalis (ZNTL)Zentalis2026-10-23 14:15 ESTCompany update

Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today presented results from an interim analysis of the DENALI Part 1b study (GOG-3066) as of a May 22, 2026 data cutoff, including the first overall survival analysis for azenosertib, at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.

Related news

ZNTLZentalis2026-10-18 22:05 EST

Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract

ZNTLZentalis2026-11-02 22:00 EST

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GSKGSK plc2026-10-23 23:00 EST

GSK presents positive data for Mo-Rez in platinum-resistant ovarian cancer

REGNRegeneron Pharmaceuticals2026-10-25 09:15 EST

Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)

RVMDRevolution Medicines2026-10-23 11:30 EST

Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026

IDYAIDEAYA Biosciences2026-10-23 10:00 EST

IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine Carcinomas

BMYBMYBristol-Myers Squibb Company2026-10-26 07:30 EST

Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study

ENTAEnanta Pharmaceuticals2026-10-26 11:00 EST

Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)

ENTAEnanta Pharmaceuticals2026-10-13 11:00 EST

Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026

MGNXMacroGenics2026-10-26 11:06 EST

MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic Cancer

View all latest news

Zentalis

Cell-Cycle Oncology Company Zentalis Pharmaceuticals develops azenosertib, an oral inhibitor of WEE1, a regulator of DNA-damage checkpoints and cell-cycle progression. Cyclin E1-Positive Ovarian Cancer The lead program targets platinum-resistant ovarian cancers with Cyclin E1 expression, where replication stress may create heightened...

Recent company news

ZNTLZentalis2026-11-02 22:00 EST

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ZNTLZentalis2026-10-23 14:15 EST

Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026

ZNTLZentalis2026-10-18 22:05 EST

Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract

ZNTLZentalis2026-10-01 21:10 EST

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ZNTLZentalis2026-09-02 20:05 EST

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

Stock data

Close: 1.71 USD
Market cap: 281.19M USD
Exchange: NASDAQ
Sector: Small Molecule Drugs
Location: United States